A fascinating Lancet RCT shows once-weekly semaglutide may redefine alcohol use disorder treatment. 🎯
In 108 adults with AUD and obesity, semaglutide reduced heavy drinking days by –13.7 percentage points vs placebo (p=0.0015) and improved craving, consumption, and biomarkers. 📉
With an NNT of ~4.3 and a manageable safety profile, GLP-1 therapy signals a shift from abstinence to precision harm reduction. 💡
Efficacy. Safety. Meaningful impact.
Is this the beginning of a new era in addiction medicine? 🧠💉
